4.44
1.55%
-0.07
After Hours:
4.4018
-0.0382
-0.86%
Summit Therapeutics Inc stock is currently priced at $4.44, with a 24-hour trading volume of 1.16M.
It has seen a -1.55% decreased in the last 24 hours and a +24.37% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.52 pivot point. If it approaches the $4.40 support level, significant changes may occur.
Previous Close:
$4.51
Open:
$4.54
24h Volume:
1.16M
Market Cap:
$3.12B
Revenue:
$956.00K
Net Income/Loss:
$-614.93M
P/E Ratio:
-2.6411
EPS:
-1.6811
Net Cash Flow:
$-76.89M
1W Performance:
-4.52%
1M Performance:
+24.37%
6M Performance:
+130.05%
1Y Performance:
+162.72%
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
44 12 3544 3939
Address
136a Eastern Avenue, Milton Park, Abingdon
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-28-18 | Downgrade | Janney | Buy → Neutral |
May-02-18 | Initiated | Janney | Buy |
Apr-12-18 | Reiterated | Needham | Buy |
Feb-13-18 | Initiated | BTIG Research | Buy |
Jan-04-18 | Initiated | SunTrust | Buy |
Dec-01-17 | Resumed | H.C. Wainwright | Buy |
Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
Oct-05-16 | Reiterated | Needham | Buy |
Sep-16-16 | Initiated | H.C. Wainwright | Buy |
Mar-30-15 | Initiated | Needham | Buy |
Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
A company insider recently bought 54321 shares of Summit Therapeutics Inc [SMMT]. Should You Buy? – Knox Daily - Knox Daily
Knox Daily
Summit Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
The InvestChronicle
Financial Snapshot: Analyzing Summit Therapeutics Inc (SMMT)'s Key Ratio Metrics – DWinneX - The Dwinnex
The Dwinnex
A significant driver of top-line growth: Summit Therapeutics Inc (SMMT) – Sete News - SETE News
SETE News
Understanding the Risks of Investing in Summit Therapeutics Inc (SMMT) – Knox Daily - Knox Daily
Knox Daily
Zurcher Kantonalbank Zurich Cantonalbank Acquires 14098 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Defense World
Summit Therapeutics Inc Stock (SMMT) Financials Data
Summit Therapeutics Inc (SMMT) Revenue 2024
SMMT reported a revenue (TTM) of $956.00 thousand for the quarter ending September 30, 2022, a -45.15% decline year-over-year.
Summit Therapeutics Inc (SMMT) Net Income 2024
SMMT net income (TTM) was -$614.93 million for the quarter ending December 31, 2023, a -680.54% decrease year-over-year.
Summit Therapeutics Inc (SMMT) Cash Flow 2024
SMMT recorded a free cash flow (TTM) of -$76.89 million for the quarter ending December 31, 2023, a -82.17% decrease year-over-year.
Summit Therapeutics Inc (SMMT) Earnings per Share 2024
SMMT earnings per share (TTM) was -$1.49 for the quarter ending December 31, 2023, a -263.41% decline year-over-year.
About Summit Therapeutics Inc
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.
Cap:
|
Volume (24h):